The cost-effectiveness of adalimumab (HUMIRA®) in patients with rheumatoid arthritis (RA) in Denmark

被引：0
|
作者：
Aagren, M.
Davies, A.
Winding, B.
Cifaldi, M.
Pang, F.
机构：
[1] Muusmann Res & Consulting, Copenhagen, Denmark
[2] United Biosource Corp, London, England
[3] Abbott Denmark AS, Gentofte, Denmark
[4] Abbott Labs, Chicago, IL USA
[5] Abbott Labs Ltd, Maidenhead, Berks, England
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2006年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of the treatment for early rheumatoid arthritis in Mexico:: Infliximab vs. adalimumab
    Mucino, E.
    Rivas, R.
    Zapata, L.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A259 - A259
  • [42] COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN IRAN
    Rezaei, S.
    Taheri, S.
    Tahmasebi, N.
    Peiravian, F.
    Yousefi, N.
    [J]. VALUE IN HEALTH, 2018, 21 : S295 - S296
  • [43] Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany; [Kosten-Nutzen-Bewertung von Adalimumab bei Rheumatoider Arthritis in Deutschland]
    Gissel C.
    Götz G.
    Repp H.
    [J]. Zeitschrift für Rheumatologie, 2016, 75 (10) : 1006 - 1015
  • [44] THE COST-EFFECTIVENESS OF LIVER-BIOPSY (BX) IN RHEUMATOID-ARTHRITIS (RA) PATIENTS ON METHOTREXATE (MTX)
    BERGQUIST, SR
    FELSON, DT
    FREEDBERG, KA
    [J]. ARTHRITIS AND RHEUMATISM, 1993, 36 (09): : S63 - S63
  • [45] THE COST-EFFECTIVENESS OF LIVER-BIOPSY (BX) IN RHEUMATOID-ARTHRITIS (RA) PATIENTS ON METHOTREXATE (MTX)
    BERGQUIST, SR
    FELSON, DT
    FREEDBERG, KA
    [J]. ARTHRITIS AND RHEUMATISM, 1993, 36 (05): : R32 - R32
  • [46] Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry
    M. Cárdenas
    S. de la Fuente
    P. Font
    M. C. Castro-Villegas
    M. Romero-Gómez
    D. Ruiz-Vílchez
    J. Calvo-Gutiérez
    A. Escudero-Contreras
    M. A. Casado
    J. R. Del Prado
    E. Collantes-Estévez
    [J]. Rheumatology International, 2016, 36 : 231 - 241
  • [47] The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis
    Incerti, Devin
    Hernandez, Ervant J. Maksabedian
    Tkacz, Joseph
    Jansen, Jeroen P.
    Collier, David
    Gharaibeh, Mahdi
    Moore-Schiltz, Laura
    Stolshek, Bradley S.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (10): : 1236 - 1242
  • [48] Evaluating the Cost-Effectiveness of Personalized Treatment with Adalimumab Using Serum Drug Levels in Rheumatoid Arthritis Patients.
    Krieckaert, Charlotte L. M.
    Nair, Sandhya C.
    Nurmohamed, M. T.
    van Dongen, Carlo J. J.
    Lems, Willem F.
    Lafeber, Floris P. J. G.
    Bijlsma, J. W. J.
    Wolbink, Gertjan
    Welsing, Paco M. J.
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S779 - S779
  • [49] COST-EFFECTIVENESS ANALYSIS OF ADALIMUMAB BIOSIMILAR COMPARED TO DELAYED BIOLOGIC TREATMENT INITIATION IN PATIENTS WITH RHEUMATOID ARTHRITIS IN GERMANY
    Porter, J.
    Stuart, P.
    Bartsch, R.
    Lebioda, A.
    [J]. VALUE IN HEALTH, 2021, 24 : S15 - S15
  • [50] Abilities to develop protective antibodies to pneumococcal and influenza vaccine are maintained in rheumatoid arthritis (RA) patients treated with adalimumab (Humira®).
    Kaine, J.
    Kivitz, A.
    Birbara, C.
    Luo, A. Y.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S515 - S516
12345